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Abstract 
This article studies the determinants of pharmaceutical innovation diffusion among 
specialists. To this end, it investigates the influences of six categories of factors—social 
embeddedness, socio-demography, scientific orientation, prescribing patterns, practice 
characteristics, and patient panel composition—on the use of new drugs for the treatment of 
type 2 diabetes mellitus in Hungary. Here, in line with international trends, 11 brands were 
introduced between April 2008 and April 2010, outperforming all other therapeutic classes. 
The Cox proportional hazards model identifies three determinants—social contagion (in the 
social embeddedness category) and prescribing portfolio and insulin prescribing ratio (in the 
prescribing pattern category). First, social contagion has a positive effect among 
geographically close colleagues—the higher the adoption ratio, the higher the likelihood of 
early adoption—but no influence among former classmates and scientific collaborators. 
Second, the wider the prescribing portfolio, the earlier the new drug uptake. Third, the lower 
the insulin prescribing ratio, the earlier the new drug uptake—physicians’ therapeutic 
convictions and patients’ socioeconomic statuses act as underlying influencers. However, this 
finding does not extend to opinion-leading physicians such as scientific leaders and hospital 
department and outpatient center managers. This article concludes by arguing that healthcare 
policy strategists and pharmaceutical companies may rely exclusively on practice location and 
prescription data to perfect interventions and optimize budgets. 
JEL code: C14, I19, O33 
Keywords: Cox proportional hazards model, diffusion, pharmaceutical innovations, 
prescribing characteristics, social contagion 
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1. Introduction 
 
Innovation and the successful diffusion of new drugs are critical for the financial performance 
of pharmaceutical companies—as well as the health of patients. At macro level, governments 
are also major influencers, both through regulatory and approval agencies and through 
budgetary allocations. The diffusion of innovation is thus determined by the strategies of 
pharmaceutical companies, government policies, as well as the behavior of medical 
professionals. This article concentrates on the last, through investigating the determinants of 
prescribing new drugs by specialists (SPs). 
 
Understanding the mechanisms leading to prescribers’ early adoption of new drugs is 
important for several reasons (Lublóy 2014). First, it accelerates diffusion. Although 
companies are increasingly innovative and efficient in producing new drugs, the 
implementation of pharmaceutical innovations is often delayed (Berwick 2003). Where new 
drugs expand therapeutics in areas of yet unmet clinical need, accelerated adoption benefits 
both medicine and society, through fast and homogeneous availability. Second, it promotes 
cost-efficiency. Healthcare systems worldwide operate with limited financial resources. When 
the same pharmacological therapy is available as different brands at different prices, 
prescribers need to select the new, more expensive brand on medical grounds rather than 
socioeconomic considerations—such as wealthy or demanding patients, for example (Ohlsson 
et al. 2009). Third, it forecasts utilization. Accurate prediction is important not only for 
pharmaceutical companies, but also for healthcare professionals and policy makers in charge 
of healthcare budget planning. Fourth, it develops targeted detailing and continuing medical 
education. Distinguishing between doctors who prescribe new drugs early and those who 
prescribe them late or never enables targeted pharmaceutical company intervention, through 
relevant, tailored information; economies of both time and money; and appropriate use of new 
drugs, through prescription of the most efficient/least expensive alternatives. 
 
Doctors have to strike a balance between using new drugs, potentially exposing patients to 
side effects, and delaying their use, depriving patients of possible benefits. The ensuing 
diffusion process is complex—although doctors consider new drugs on individual merits, 
some may be more predisposed to adopt than others. Several factors are significantly 
positively associated with early adoption of new drugs (Lublóy 2014): (1) physicians’ interest 
in particular therapeutic areas, participation in clinical trials, and prescribing volume, either in 
total or within the therapeutic class of the new drug (for example, Coleman et al. 1966; Glass 
& Rosenthal 2004; Lin et al. 2011; Liu & Gupta 2012); (2) pharmaceutical companies’ 
marketing efforts (for example, Kremer et al. 2008; Manchanda et al. 2008, Iyengar et al. 
2011; Liu & Gupta 2012); (3) social interactions among colleagues, with pharmaceutical sales 
representatives, and with patients (for example, Coleman et al. 1966; Manchanda et al. 2008; 
Iyengar et al. 2011; Lin et al. 2011; Liu & Gupta 2012)—colleagues are indispensable to 
gaining knowledge and reduce uncertainty about the consequences of new drug adoption 
(Peay & Peay 1994; McGettigan et al. 2001; Prosser & Walley 2006); and (4) physicians with 
younger patients, patients with higher socioeconomic statuses, and/or patients with poorer 
health statuses (for example, Mark et al. 2002; Greving et al. 2006; Ohlsson et al. 2009; Liu et 
al. 2011). Some (5) socio-demographic factors and (6) practice-related factors also play 
important—albeit lesser—roles in the diffusion process. 
 
This article acknowledges the variety of variables likely to influence new drug uptake—and 
the likely prominent role of social interactions—and sets to answer two research questions. 
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First, do social interactions with former classmates, scientific collaborators, and 
geographically close colleagues influence the likelihood of adoption equally? Second, which 
prescribing characteristics predict new drug uptake consistently across various drugs from the 
same therapeutic class? Predicting physicians’ prescribing behaviour is a complex, 
multifactoral exercise. However, patients, physicians, policymakers, and pharmaceutical 
companies would all benefit from understanding the influencing factors and their interactions. 
The large-scale model suggested here would particularly benefit healthcare policy 
strategists—with perfecting their interventions—and pharmaceutical companies—with 
optimizing their marketing budgets. 
 
This article contributes to the literature in two ways. First, by investigating the presence of 
social contagion (also known as interpersonal network effect, word-of-mouth effect, or peer 
influence), where individual adoption behaviors regarding a new drug are affected by 
exposure to others’ knowledge, attitudes, or behaviors in relation to that drug. In particular, 
this article assesses the impacts of three types of social interaction—with former classmates, 
with scientific collaborators, and with geographically close colleagues. To the authors’ 
knowledge, the influences of the first two social networks on new drug diffusion have never 
been analyzed in the pharmaceutical literature before, whereas a contagion measure 
aggregating the adoption behaviors of geographically close colleagues for each physician was 
used in only two recent studies (Manchanda et al. 2008; Liu & Gupta 2012). However, 
anecdotal evidence shows that physicians regularly exchange ideas with former classmates 
(Bajaj 2012; Wong 2014), whereas the influential role of scientific collaborators was proved 
in many other domains (Glänzel & Schubert 2005; Liu et al. 2005; Acedo et al. 2006; Huesch 
2011). This article is therefore a pioneering attempt at documenting influences from such 
social interactions on new drug diffusion. 
 
Second, by investigating a wide range of potential additional determinants. To the authors’ 
knowledge, potential additional determinants of new drug uptake have not survived prior 
rigorous analysis: no other study has ever analyzed such a variety of variables, or indeed 
included so many new drugs from the same therapeutic class (for example, Coleman et al. 
1966; Greving et al. 2006; Iyengar et al. 2011; Lin et al. 2011; Bourke & Roper 2012). This 
article considers the influences of five ‘classical’ categories of factors—physicians’ socio-
demographies, scientific orientations, and prescribing patterns, as well as practice 
characteristics and patient-related factors. The total of 22 factors serves to identify 
determinants—variables consistently predicting new drug diffusion—for the 11 drugs recently 
introduced in one therapeutic class. Pharmaceutical companies and healthcare policy 
strategists alike could accelerate new drug diffusion by focusing on the most influential 
categories of factors—identified here through the rigorous evidence of prescription data rather 
than the survey and mail questionnaire approach of most prior research (Chauhan & Mason 
2008; Mason 2008). Exempt from recall and social desirability biases, prescription data 
reflect prescribing realities—including the personal and behavioral traits of prescribing 
physicians as well as the influences associated with marketing activities, evidence bases, peer 
pressures, and regulatory environments. 
 
Following this introduction, section 2 presents the key characteristics of the study drugs and 
the data sources used, discusses the statistical model, and specifies the independent variables. 
Section 3 presents the results, which are then discussed in section 4, alongside policy 
implications. Section 5 analyzes several possible research limitations. Finally, section 6 
summarizes the research findings. 
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2. Methods 
 
2.1. Study drugs 
 
This article focuses on new anti-diabetic drugs (A10Bs
2
) for the treatment of type 2 diabetes 
mellitus (T2DM) in Hungary for four reasons. First, pharmaceutical companies are keen to 
develop such drugs, due to increasingly high potential market—347 million people worldwide 
suffer from diabetes (Danaei et al. 2011), projected to become the seventh cause of death in 
2030 (WHO 2011). In Hungary alone, 11 brands were introduced in a subsidized form 
between April 2008 and April 2010, outperforming all other therapeutic classes—the 
Hungarian National Health Insurance Fund (NHIF) recognized both the urgent therapeutic 
need and the new drugs’ therapeutic efficacy (for main data, see Table 1; for supplementary 
data, see online Appendix). When added to metformin, the default treatment for T2DM, all 11 
A10Bs reduce the HbAc1 level—with close to equal efficiencies, and despite distinct modes 
of action. 
 
Table 1: New anti-diabetic drugs introduced in Hungary between April 2008 and April 2010: 
main data 
 
Brand 
name 
ATC
a
 
code  
Active 
ingredient 
FDA
b
 
therapeutic 
novelty 
Distribution 
rights 
Subsidized 
introduction 
date 
Cumulative 
DOT
c
 (as of 
December 
2011) 
Market share
d
 (as 
of December 
2011, in 
percentages) 
Actos A10BG03 pioglitazon 
new 
molecular 
entity 
Takeda 
Global 
Research 
April 2008 43,848 3.00 
Byetta A10BX04 exenatide 
new 
molecular 
entity 
Eli Lilly 
Nederland 
April 2010 23,360 1.60 
Competact
e
 A10BD05 
metformin; 
pioglitazon 
new 
combination 
Takeda 
Global 
Research 
June 2009 171,500 11.75 
Eucreas A10BD08 
metformin; 
vildagliptin 
without FDA 
approval 
Novartis 
Europharm 
November 
2008 
396,540 27.16 
Galvus A10BH02 vildagliptin 
without FDA 
approval 
Novartis 
Europharm 
November 
2008 
54,278 3.72 
Janumet A10BD07 
metformin; 
sitagliptin 
new 
combination 
Merck Sharp 
& Dohme 
February 
2009 
288,764 19.78 
Januvia A10BH01 sitagliptin 
new 
molecular 
entity 
Merck Sharp 
& Dohme 
August 2008 104,020 7.12 
Onglyza A10BH03 saxagliptin 
new 
molecular 
entity 
Bristol-
Myers 
Squibb 
April 2010 74,850 5.13 
Velmetia A10BD07 
metformin; 
sitagliptin 
new 
combination 
Merck Sharp 
& Dohme 
April 2009 200,004 13.70 
Victoza A10BX07 liraglutide 
new 
molecular 
entity 
Novo 
Nordisk 
April 2010 52,080 3.57 
                                                 
2
 The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification for blood 
glucose (HbAc1) lowering drugs other than insulin, based on the organs/systems on which drugs act and/or the 
therapeutic and chemical characteristics of the drugs. 
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Xelevia A10BH01 sitagliptin 
new 
molecular 
entity 
Merck Sharp 
& Dohme 
April 2009 50,834 3.48 
a
 Anatomical Therapeutic Chemical. 
b
 Food and Drug Administration. 
c
 Days of therapy. 
d
 Relative to the other new A10Bs. 
e
 Actoplus Met, in the US. 
 
Second, all 11 study drugs are first-in-class, with new ATC codes and—with two 
exceptions—Food and Drug Administration approval, either as new molecular entities (the 
highest of ten levels of drug novelty) or as new combinations. 
 
Third, prescribing A10Bs in a subsidized form involves considerable medical complexity and 
a well-defined group of SPs, mostly internists subspecialized in endocrinology—a fairly 
‘closed’ community, suitable for the purpose of this article. 
 
Fourth, the care of T2DM patients is shared between general practitioners (GPs) and SPs, 
allowing for the examination of routine—as opposed to just first-time—adoption of new 
A10Bs. Adoption becomes routine when SPs first ask referring GPs to prescribe new A10Bs, 
on grounds of efficacy and efficiency. Intuitively, any such drugs are already part of the SPs’ 
prescribing portfolios, following first-time adoption and follow-up tests. 
 
2.2. Data sources 
 
For covariates, this article uses two main and five additional databases (see the third columns 
in Tables 2 and 3). 
 
One of the two main databases is managed by DoktorInfo Ltd and covers prescription 
information between April 2008 and December 2011. All GPs in Hungary are required by law 
to collect data for NHIF. Of these, 899 (22 per cent) also feed real-time prescription data into 
the DoktorInfo database voluntarily—they are representative of the entire Hungarian GP 
population in both age and location (defined by region and population size). This involves no 
additional work for GPs, who are compensated for providing information such as GP 
identification number; prescription date; prescribed drug characteristics (brand name, ATC 
code, and dosage); prescribed drug subsidy; patient characteristics (age and gender); and, 
since January 2009, for patients whose care is shared, identification number of the therapy-
initiating SP. The latter enables monitoring the adoption behaviors and prescribing patterns of 
SPs who share care of T2DM patients. 
 
The other is managed by the Office of Health Authorization and Administrative Procedures 
(OHAAP) and covers socio-demographic and practice-related variables as well as physician 
characteristics (see Table 3), which contribute to generating social embeddedness and 
scientific orientation metrics. 
 
The five additional databases are GeoX, an integrated statistical database providing 
consolidated and structured spatial datasets for every NUTS
3
 level in Hungary; ComFit, a 
bibliographic database similar to PubMed and containing Hungarian medical articles; the 
                                                 
3
 Nomenclature of Units for Territorial Statistics. 
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Hungarian Diabetes Association (HDA), with information on the scientific activities of 
qualified diabetologists (HDA board memberships, HDA award receiverships, editorships, 
and presentations at the HDA biennial congresses); the Hungarian Central Statistical Office 
(HCSO), with information on settlement sizes; and Google Maps, with information which 
allows the calculation of distances among SPs. 
 
2.3. Statistical model 
 
Similarly to many recent diffusion studies (for example, Korda et al. 2011, Lin et al. 2011), 
this article uses the Cox proportional hazards model (Cox 1972) to examine factors 
influencing the likelihoods of routine adoptions of A10Bs by SPs. The Cox model is the most 
appropriate choice for the purpose because of the way it handles right-censored data. That is, 
cases where SPs had not routinely adopted the A10Bs by the end of 2011 (time t), and where 
the hazard ratio/likelihood of routine adoption at time t for each SP is 
h(t)=λ0exp(β1X1+β2X2+…+βkXk), 
with λ0 the baseline hazard function, exp(βi) the i
th
 hazard ratio, and Xi the i
th
 independent 
variable (which can be time invariant or time varying during observation). For multiple highly 
correlated covariates (with coefficients higher than 0.65), only one variable from the set of 
intercorrelated variables is used. 
 
The dependent variable is a dummy indicating each month whether the SP had routinely 
adopted the A10B. 
 
2.4. Independent variables 
 
This article considers social contagion and five categories of quantitatively measurable factors 
relevant to prescribing behavior. Tables 2 and 3 summarize the descriptive statistics for time-
dependent covariates and respectively time-independent covariates—the 318 SPs in the 
sample share at least 20 patients with any of the 899 GPs in the DoktorInfo database. Lublóy 
(2014) documented the characteristics of early adopters and differentiated between variables 
consistently predicting new drug uptake and variables producing inconsistent results, 
providing guidance for the variables considered here and their expected signs. 
 
Table 2: Contagion measures: definitions and descriptive statistics for 318 SPs 
 
Social network Link Data source 
Number of 
links 
Network density 
(in percentages) 
former classmates 
graduating from the same medical 
establishment in the same year 
OHAAP 330 0.65 
scientific 
collaborators 
coauthoring at least one article in 2009–13/co-
preparing at least one HDA congress 
presentation in 2006/2008 
ComFit; 
HDA 
151 0.30 
geographically close 
colleagues 
practicing within 35 kilometers/22 miles of at 
least two other SPs 
Google 
Maps; 
OHAAP 
4,856 9.63 
 
Contagion measures assess whether the adoption decisions of colleagues significantly 
influence SPs’ likelihoods of routine adoption—they are time-dependent covariates, the 
percentage of adopting colleagues changing over time. To ensure causal relationships between 
explanatory and time-dependent covariates, the latter were lagged by one month. 
Interactions—professional and social—appear to be a very important influencing factor, 
information relayed through direct, personal contacts proving particularly powerful. 
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Physicians’ adopting behaviors are affected by other physicians’ knowledge, attitudes, and 
behaviors, thus reducing safety and efficacy uncertainties. Interactions with opinion-leading 
physicians seem critical to fast, wide acceptance of medical innovations (Williamson 1975; 
Peay & Peay 1994; McGettigan et al. 2001; Prosser & Walley 2006; Huesch 2011). While 
other sources of information provide the nurturing groundwork of necessary knowledge, 
behavioral change requires the legitimizing power of personal advice from informed and 
respected colleagues through reliable, easy-to-digest assessments of new drugs. Van den Bulte 
& Lilien (2001) aside, studies found strong, convincing empirical evidence of social 
contagion in new drug adoption even after controlling for a wide variety of factors (Coleman 
et al. 1966; Manchanda et al. 2008; Iyengar et al. 2011; Lin et al. 2011; Liu & Gupta 2012)—
adding contagion measures to the model is inevitable and identifying proper social networks 
is crucial to constructing them. Four of the six studies asked SPs to list their collegial 
interactions (Coleman et al. 1966; Van den Bulte & Lilien 2001; Iyengar et al. 2011; Lin et al. 
2011)—survey-based contagion measures capture interpersonal effects directly, but are time 
consuming and costly and suffer from bias, low response rate, and endogenous group 
formation (Liu & Gupta 2012). Well-established in the broader literature, geographic 
proximity is an alternative approach to defining social networks in pharmaceutical contexts 
(Manchanda et al. 2008; Liu & Gupta 2012), capturing interpersonal effects indirectly, but 
objectively and easily. 
 
This article uses complementary data sources to construct three contagion measures which 
reflect distinct channels of interpersonal communication—with former classmates, with 
scientific collaborators, and with geographically close colleagues. Former classmates 
graduated from the same medical establishment in the same year (OHAAP), scientific 
collaborators either published an article (ComFit) or prepared a presentation (HDA) together, 
and geographically close colleagues had offices within a pre-specified radius (Google Maps). 
Manchanda et al. (2008) argued that a radius of 20 miles is long enough to capture most of the 
interpersonal effects and short enough to allow social network differentiations. This article 
defines SPs’ spatial social networks through geographic circles with radiuses of 35 
kilometers/22 miles centered on SPs’ practice locations, radius sensitivity double-checked by 
additional radiuses at ±20 per cent. 
 
Table 3: Time-independent covariates: definitions and descriptive statistics for 318 SPs, with 
proportional and per patient values calculated over the two-year period 2010–11 
 
Variable Description Data source Mean Min. Max. 
St. 
dev. 
SOCIO-DEMOGRAPHIC CHARACTERISTICS 
gender 
gender of the SP (in percentages) 
male 
OHAAP 
47.80 
n/a 
female 52.20 
age age of the SP (as of December 2013) 51.92 32.00 78.00 9.94 
training 
location 
location of university where the first medical degree was earned (in percentages) 
capital 
OHAAP 
34.28 
n/a 
southwest 19.81 
northeast 22.96 
southeast 16.04 
overseas 6.92 
SCIENTIFIC ORIENTATION 
number of 
specialties 
number of specialties earned by the SP OHAAP 1.78 1 4 0.78 
publication 
record 
number of publications by the SP (between January 2009 
and June 2013) 
ComFit 2.07 0 136 9.26 
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position 
position of the SP (in percentages) 
high ((deputy) head of hospital department or 
outpatient centre) 
OHAAP 
22.30 
n/a 
medium (chief physician) 33.30 
low (associate professor or physician) 44.30 
scientific 
commitment 
dummy variable for HDA board membership, HDA award 
receivership, or chief editorship 
HDA 0.04 0 1 n/a 
PRESCRIBING CHARACTERISTICS 
prescribing 
intensity 
mean number of prescription initiations per patient 
DoktorInfo 
12.71 4.63 30.93 3.72 
portfolio width number of brands prescribed for patients in shared care 16.66 4 25 4.13 
insulin ratio 
prescriptions initiating treatment with insulin (in 
percentages) 
79.10 0.00 100.00 20.84 
old A10B ratio 
prescriptions initiating treatment with previously 
introduced A10Bs (in percentages) 
2.99 0.00 33.33 4.66 
PATIENT CHARACTERISTICS 
age age of patients on the SP’s patient panel 
DoktorInfo 
64.20 44.00 72.87 2.84 
gender male patients on the SP’s patient panel (in percentages) 47.07 7.02 70.37 7.39 
income 
mean annual income of patients on the SP’s patient panel, 
proxied by either the mean street-level income (for large 
settlements, over 20 thousand inhabitants) or the zip code-
level income (for small settlements, under 20 thousand 
inhabitants) (in EUR) 
GeoX 3,103 1,267 5,040 597 
health status 
patients with comorbidities on the SP’s patient panel (in 
percentages) 
DoktorInfo 45.25 0.00 100.00 21.94 
PRACTICE CHARACTERISTICS 
number of 
patients 
number of the SP’s T2DM patients whose care is shared 
with GPs 
DoktorInfo 
123.48 14 784 114.71 
number of 
referring GPs 
number of GPs with whom the SP share cares patients 21.56 1 84 15.95 
number of 
consultations 
mean number of consultations per patient resulting in 
confirmation or change of prescription by the SP 
1.68 1.00 2.85 0.37 
proportion of 
loyal patients 
patients consulting the same SP (in percentages) 70.77 17.54 100.00 19.76 
location 
size of city where the SP works, proxied by number of inhabitants (in percentages) 
capital (over 1 million) 
HCSO, 
OHAAP 
21.7 
n/a 
large city (100 thousands–1 million) 28.6 
medium-sized city (40–100 thousands) 14.8 
small city (under 40 thousands) 34.9 
type 
institution where the SP’s practice is embedded (in percentages) 
clinic 
OHAAP 
10.7 
n/a 
university/teaching hospital 11.6 
hospital 60.7 
outpatient centre and others 17.0 
number of 
workplaces 
number of the SP’s current affiliations 1.46 0 5 0.69 
 
Previous empirical research suggested that SPs’ socio-demographic characteristics—gender, 
age, and training location—are either significantly associated with new drug uptake or play a 
controversial role in the adoption process, both cases being worth analyzing (Lublóy 2014). 
Gender played an influential role in the early adoption of new drugs in seven of 15 studies, 
male prescribers being more likely to adopt new drugs than female prescribers. Age was 
associated with new drug uptake in nine of 14 studies—in seven, early prescribers were 
younger than the majority. Four of five studies found training location influential. 
 
SPs’ scientific orientation—measured by number of specialties, publication record, position, 
and scientific commitment—is a fairly under-researched area. Previously, only position was 
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included in only one of 35 studies deemed eligible for review (Lublóy 2014)—hospital 
doctors in managerial or honorary positions were found to adopt new drugs later than others, 
due to limited involvement in actual medical practice (Van den Bulte & Lilien 2001). 
 
Empirical evidence showed that prescribing characteristics are crucial in new drug uptake 
(Lublóy 2014)—this article includes prescribing intensity, portfolio width, and the ratios of 
prescriptions for insulin and old A10Bs. Due to high correlation between number of patients 
and prescribing volume (0.95), prescribing intensity is captured by the ratio of prescriptions 
per patient. Increases in portfolio widths—that is, in the number of brands prescribed—may 
decrease times to adoption, its very high explanatory power demonstrated by Bourke & Roper 
(2012). Ten of 11 studies found that the higher the prescribing volume in the therapeutic class 
of a new drug, the higher the likelihood of early adoption of that new drug, due to enhanced 
adoption risk and likelihood of patients matching the recommended patient profile (Lublóy 
2014). Differences in ratios of prescriptions for insulin and old A10Bs may be due to SPs’ 
individual attitudes towards available therapies, a matter of continuous debate in the medical 
literature (Krentz & Bailey 2005; Scheen 2005; Fonseca & Kulkarni 2008). 
 
Prior research suggested that four patient characteristics may exert significant influence on 
new drug uptake—age, gender, socioeconomic status, and health status (Lublóy 2014). Five 
of nine studies reported that physicians are less likely to prescribe new drugs to elderly 
patients, more likely to experience side effects. While gender exerts little influence, the 
socioeconomic and health statuses are critical in new drug uptake. Three of four studies found 
that high-income patients receive new drugs earlier than others, not least because of their 
ability to pay for out-of-pocket treatments. Similarly, patients’ health statuses—self-reported 
health, poor response to existing therapies, previous use of certain medications, and presence 
of comorbidities—played an influential role in new drug uptake in three of four studies. Here, 
socioeconomic status is measured through income and health status through the presence of 
comorbidities. 
 
Of the seven practice characteristics, size deserves obvious investigation—intuitively, the 
larger the size, the higher the probability of patients with T2DM. Here, size is measured by 
number of patients and number of referring GPs, as a proxy for the size of the catch area. The 
therapeutic activities—proxied by number of consultations per patient—were associated 
positively with early adoption of new drugs in all the eligible studies (Lublóy 2014). High 
volumes of diagnostic and therapeutic activities may be indicative of patient health severity, 
and of the need for early adoption of new drugs. Proportion of loyal patients has never been 
assessed in the literature before, although SPs may be more inclined to prescribe new drugs to 
patients whose medical histories they already know. Prior research suggested that location 
and type may also play a role in new drug diffusion (Lublóy 2014). With fewer opportunities 
for professional interactions and less frequent visits by pharmaceutical sales representatives, 
physicians in small cities might adopt new drugs later than colleagues in large cities—a view 
supported by three of the seven eligible studies, at least partly (Lublóy 2014). Two previous 
studies assessed type with contradictory results, worth clarifying (Lublóy 2014)—one study 
found no significant association between institutional accreditation and new drug uptake 
(Iyengar et al. 2011), whereas the other found evidence of association (Liu et al. 2011). Two 
studies looked into number of workplaces with ambiguous conclusions, also worth 
investigating—Garcia Lirola et al. (2000) found that doctors with more than one workplace 
adopted new drugs earlier than others, whereas Lin et al. (2011) found the number of 
workplaces irrelevant. 
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3. Results 
 
The 318 physicians analyzed here accounted for roughly 80 per cent of the SPs who treated 
T2DM on a daily basis (see Tables 2 and 3 for basic statistics). They were 51.92 years old, on 
average, and 152 (47.8 per cent) were male—109 (34.28 per cent) had graduated from 
Semmelweis University in Budapest, the oldest medical school in Hungary. On average, they 
had furthered their medical education in 1.78 specialties and had published 2.07 articles. 
Nearly half (157, 49.37 per cent) had published at least one article—43 (13.52 per cent) had 
published more than four. Approximately one fourth (71, 22.3 per cent) held a high-status 
position. Fourteen SPs displayed intense scientific commitment to diabetes, and could be 
considered opinion leaders in the area. 
 
The combined 33,448 patients received 499,131 specialist medication prescriptions from their 
GPs. A typical SP suggested therapies for 123.48 patients and asked GPs to write 1,570 
prescriptions—12.71 prescriptions per patient. (S)he prescribed almost 17 brands within the 
therapeutic class—the mean ratio of prescriptions was 79.1 per cent for insulin and 2.99 per 
cent for old A10Bs. 
 
The mean age of patients was 64.2 years, and their average annual income was EUR 3,103. 
On average, 45.25 per cent of the patients on the SPs’ panels had at least one comorbidity. 
 
A typical SP received referrals from 21.56 GPs and saw patients 1.68 times. Over two thirds 
of patients (23,671, 70.77 per cent) were loyal to their SPs and did not consult other SPs in the 
sample. Approximately one fourth of SPs (69, 21.7 per cent) practiced in Budapest, whereas 
one third (111, 34.9 per cent) in small cities. The majority (193, 60.7 per cent) worked in a 
non-university/teaching hospital. On average, SPs were affiliated to 1.46 institutions. 
 
The regression results for the 11 study drugs (see Table 4) represent exp(β)s—hazard ratios 
between two SPs when the values of the respective variables differ by one unit, all other 
covariates being held constant. Variables with exp(β)s larger than one are associated with 
increased hazard—the higher the variable, the higher the hazard of the event. 
 
The social influence from colleagues within a 35-kilometer radius is an important predictor of 
new drug uptake—the adoption ratio is positively associated with the likelihood of initial 
adoption for seven brands (Actos, Byetta, Competact, Eucreas, Galvus, Janumet, and 
Januvia). Counterintuitively, former classmates significantly delay the diffusion process for 
one brand (Byetta) and scientific collaborators for four brands (Galvus, Januvia, Onglyza, and 
Xelevia). In rest, exchanges within social networks do not influence significantly the 
likelihood of initial adoption. 
 
The number of brands individual SPs prescribe is a very influential predictor of new drug 
uptake—the wider the prescribing portfolios, the earlier SPs initiate new therapies, for all 11 
brands, whereas the ratio of prescriptions for insulin is significantly negatively associated for 
nine brands (Byetta, Competact, Eucreas, Galvus, Janumet, Januvia, Onglyza, Velmetia, and 
Xelevia). 
 
At 95 per cent-confidence level, the majority of variables are significantly associated with the 
likelihood of initial adoption for only one or two brands—their number ranges from two 
(Victoza) to seven (Velmetia and Xelevia). In nine cases, the signs are as hypothesized based 
on previous empirical evidence (Lublóy 2014)—new drugs are adopted earlier by young SPs 
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(Victoza) and SPs with outstanding publication records (Velmetia), strong scientific 
commitments (Xelevia), large patient panels (Eucreas), high prescribing intensities (Janumet), 
high consultation intensities (Actos and Eucreas), younger patients (Byetta), more female 
patients (Velmetia), and high-income patients (Velemtia). In six other cases, the signs are 
counterintuitive, with higher likelihoods of initial adoption for female (Xelevia) and older SPs 
(Competact) and SPs with weak scientific commitments (Velmetia), less experience of old 
A10Bs (Galvus and Xelevia), older patients (Velmetia), and proportionally fewer loyal 
patients (Competact and Janumet). Seven variables have no explanatory power—training 
location, number of specialties, position, number of workplaces, number of referring GPs, 
practice location, and practice type. 
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Table 4: The Cox model regression results 
 
Category Variable Actos Byetta Competact Eucreas Galvus Janumet Januvia Onglyza Velmetia Victoza Xelevia 
contagion measures 
former classmate 1.008 0.841
*
 0.981 0.996 1.016
†
 0.984
†
 0.986
†
 0.980 1.012 0.988 1.006 
scientific collaborator 0.972
†
 0.001 0.984 1.006 0.954
*
 1.003 0.966
*
 0.804
**
 1.031 1.089
†
 0,880
**
 
geographic proximity (35 km) 1.082
***
 1.204
*
 1.048
*
 1.032
*
 1.052
**
 1.032
*
 1.044
**
 0.924 1.010 0.984 1.005 
geographic proximity (28 km) 1,070
***
 1,170
†
 1.028 1.036
**
 1.044
**
 1.036
*
 1,040
**
 0.960 1.015 0.999 0.987 
geographic proximity (42 km) 1.074
***
 1.202
†
 1.048
†
 1.033
*
 1.057
**
 1.039
*
 1.043
**
 0.898
†
 1.015 0.975 1.008 
SPs’ socio-demographic characteristics 
gender 1.139 0.889 1.034 0.911 0.879 0.769
†
 1.131 0.997 1.099 0.884 1.542
*
 
age 0.991 0.992 1.021
*
 1.001 0.997 1.000 1.006 0.979
†
 0.993 0.963
**
 0.978
†
 
training location 0.934 1.151 1.014 1.085 0.996 0.998 0.983 0.957 1.077 0.973 1.004 
SPs’ scientific orientation 
number of specialties 0.909 0.992 0.884 1.151
†
 0.961 1.168 1.034 1.046 0.979 0.977 1.164 
publication record 1.011 0.972 0.994 0.999 0.988 1.005 0.998 1.011 1.042
***
 1.009 0.994 
position 0.887 0.903 1.117 1.062 0.996 0.992 1.018 0.858 0,810
†
 0.994 0.749
†
 
scientific commitment 1.202 2.632 1.122 0.828 0.745 0.713 1.239 0.216
†
 0.342
*
 1.842 3,050
*
 
SPs’ prescribing characteristics 
prescribing intensity 0.951 1.114
†
 1.037 0.974 0.994 1,080
*
 1.015 1.010 0.992 1.033 1.014 
portfolio width 1.244
***
 1.392
***
 1.263
***
 1,120
***
 1.187
***
 1.207
***
 1.173
***
 1.228
***
 1.211
***
 1.342
***
 1.253
***
 
insulin ratio 1.005 0.956
***
 0.987
**
 0,980
***
 0.974
***
 0.973
***
 0.984
***
 0.971
***
 0.982
**
 1.013 0.962
***
 
old OAB ratio 1.035 0.933 0.999 0.996 0.945
*
 1.017 0.965 0.961 0.976 0.997 0.917
*
 
patient characteristics 
age 1.029 0.862
*
 0.978 0.991 1.016 0.988 0.984 0.993 1.072
*
 0.971 1.052 
gender 1.005 1.028 0.990 1.003 0.995 0.982
†
 0.984 1.026
†
 1.025
*
 1.001 1.008 
income 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1,000
*
 1.000 1.000 
health status 1.009
*
 0.990 1.003 1.002 1.005 1.000 1.007
*
 0.994 1.005 0.991 1.009 
practice characteristics 
number of patients 1.002
†
 1.001 0.999 1.003
***
 1.000 1.001 1.001 1.002
†
 1.000 1.000 0.999 
number of referring GPs 0.996 1.003 1.011 0.990 1.000 1.004 1.003 0.999 1.009 0.991 1.009 
consultations per patient 2.712
**
 0.739 1.722
†
 2.277
***
 1.235 0.786 1.530 1.251 1.059 1.231 1.499 
proportion of loyal patients 0.994 0.986 0.983
***
 1.001 1.000 0.988
**
 1.001 1.003 0.998 1.004 1.006 
practice location 0.843 0.722 1.119 0.943 1.004 0.996 0.945 1.037 1.037 0.949 1.070 
practice type 1.261
†
 0.958 0.985 0.898 0.858 1.138 0.975 1.008 1.157 0.862 0.985 
number of workplaces 1.116 0.713 1.025 0.988 1.094 1.020 1.104 0.898 1.146 0.907 1.126 
Omnibus test 157.894
***
 60.781
***
 152.306
***
 156.76
***
 87.699
***
 151.435
***
 118.584
***
 119.609
***
 148.677
***
 101.9
***
 106.528
***
 
†
 p<0.1 
* p<0.05 
** p<0.001 
*** p<0.0001 
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4. Discussion and policy implications 
 
This article studied the influences of a wide range of variables on the SPs’ adoption of new drugs 
and identified three key determinants—contagion from geographically close colleagues, portfolio 
width, and insulin ratio. 
 
The higher the adoption ratio of geographically close colleagues, the higher the likelihood of early 
adoption for seven of the 11 brands. Two earlier pharmaceutical studies reached identical 
conclusions—Manchanda et al. (2008) and Liu & Gupta (2012) both reported that the estimated 
effect of social contagion among physicians in geographic proximity is positive and significant even 
after controlling for time trends and marketing efforts. However, due to data constraints, this article 
could not control for detailing—some sales representatives may be more persuasive than others and 
may operate in geographies where physicians are more inclined to adopt new drugs, a propensity 
further enhanced by peer pressures from nearby adopters. At least initially, pharmaceutical 
companies and healthcare policy strategists wishing to influence new drug diffusion need to focus 
on geographies where practices are close—larger cities, with higher population densities and family 
incomes—and on monetary aspects and the sales representatives’ persuading powers. 
 
However, this article found no empirical evidence for the hypothesized influential roles of former 
classmates and scientific collaborators—in a few cases, these had even delayed diffusion. 
Geographically close colleagues form the densest social network, whereas scientific collaborators 
the sparsest (see Figure 1). More likely than not, former classmates discuss professional matters 
irregularly, whereas scientific collaborators exchange ideas regularly, at least in writing. However, 
their networks are small, sparse, and temporal—only roughly one third of the SPs in the sample had 
ever published an article with a colleague. To disentangle the eventual exception from the rule more 
research is required—it is easier to construct former classmate and scientific collaborator networks 
than it is to construct survey-based networks. 
 
A recent study showed that collegial interactions within a medical establishment influence the 
likelihoods of initial prescriptions—both compeers and senior colleagues play crucial roles (Lin et 
al. 2011). However, to the authors’ knowledge, there are no rigorous analyses as to how collegial 
interactions outside the workplace—through continuing medical educations, national and 
international conferences, and professional memberships—affect new drug uptake. 
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Figure 1: Social networks of specialists: (a) geographically close colleagues; (b) former classmates 
at Semmelweis University; and (c) scientific collaborators 
 
(a) 
 
318 SPs
4 856 links
12 clusters
 
 
(c) 
 
90 SPs
 151 links
14 clusters
 
 
(b) 
 
93 SPs
 137 links
 28 clusters
 
 
 
Portfolio width is the only consistent predictor across the 11 study drugs, in line with Bourke & 
Roper (2012), who—out of over ten variables—found significant and consistently signed effects 
across six new drugs used in general practice. The wider the portfolios, the shorter the physicians’ 
adoption times. 
 
Of note, portfolio width correlates highly with number of patients (0.65), which in turn correlates 
highly with prescribing volume in the therapeutic class of the new drug (0.95). When portfolio 
width is excluded from the Cox model, number of patients becomes the only consistent predictor of 
new drug uptake. When number of patients is excluded, prescribing volume in the therapeutic class 
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of the new drug becomes the only consistent predictor of early adoption, in line with Lublóy (2014), 
where physicians with high patient flows seemed particularly alert to new drugs—in six of nine 
studies, the higher the total number of patients (or total prescribing volume), the higher the 
likelihood of early adoption. Moreover, almost all eligible studies—ten out of 11—found that the 
higher the prescribing volume in the therapeutic class of a new drug, the higher the likelihood of 
early adoption of that new drug. However, the regression results here show that portfolio width is a 
better predictor of new drug uptake than either total number of patients (or total prescribing 
volume) or prescribing volume in the therapeutic class of the new drug. Previous studies might have 
drawn identical conclusions, had portfolio width been considered. 
 
Another important determinant, ratio of prescriptions for insulin is significantly negatively 
associated with the rate of adoption for nine of the 11 study drugs, with four possible explanations 
for delays in the adoption of new A10Bs. First, the individual SPs’ convictions as to the most 
appropriate therapy (Krentz & Bailey 2005; Scheen 2005; Davis & Abraham 2011), which may be 
related to therapeutic conservatism or to knowledge of and clinical experience with the new A10Bs. 
Second, patients with long disease histories, predating A10Bs, had already received insulin, thus 
excluding A10Bs as an alternative therapy (Korytkowski 2002; Krentz & Bailey 2005). Third, for 
patients at severe stages of the disease, A10Bs are insufficient for keeping blood glucose levels low. 
Fourth, low-income patients cannot cover 30 per cent of the A10B price, whereas insulin is free of 
charge. However, the latter three explanations can be ruled out, at least partly. The mean patient 
age—presumably, a good proxy for the length of the disease history—was factored in and found 
significantly associated with the uptake of Velmetia, but not with the other ten A10Bs. Furthermore, 
prescribing Velmetia was associated with older rather than younger patients. Disease severity was 
measured through the presence of comorbidities, and no significant associations were found with 
new drug adoption. Finally, the mean annual patient income was also factored in and found 
significantly positively associated with the uptake of Velmetia, but not of the other ten A10Bs. 
However, two estimation biases may affect validity. First, patient income was proxied by either the 
mean street-level income (for large settlements, over 20 thousand inhabitants) or the zip code-level 
income (for small settlements, under 20 thousand inhabitants). Second, the shadow economy is 
sizeable in Hungary and reported and actual incomes may differ significantly. However, further 
investigation of these biases is beyond the scope of this article. Furthermore, discussions with 
physicians support the idea that SPs favor insulin either due to therapeutic convictions or to having 
low-income patients—the impact of both factors was supported by evidence in the diffusion 
literature (Lublóy 2014). 
 
The three determinants of new drug diffusion identified here belong to two categories of factors—
contagion measures and prescribing characteristics. This may be considered good news for 
pharmaceutical companies and healthcare policy strategists, who need to rely only on these two 
categories to influence new drug diffusion—all other categories seem irrelevant to prescribing 
behavior. To rollout new drugs successfully, practice location and prescription data may be 
sufficient to identify target SPs, distribute marketing efforts, and allocate healthcare budgets. Hard-
to-obtain data such as SPs’ socio-demographic characteristics and scientific orientations and 
practice and patient characteristics are not necessary. 
 
A number of variables do not influence the likelihood of routine adoption significantly. There is no 
evidence that physicians in high positions adopt later, as suggested by Van den Bulte & Lilien 
(2001)—as knowledge brokers with ambassadorial roles and high legitimacies (Waring et al. 2013), 
hospital department and outpatient center managers did not adopt significantly later any of the 
brands. Measured through HDA board membership, HDA award receivership, and senior 
editorship, opinion leaderships do not lead to significantly different likelihoods of routine adoption. 
Presumably, other SPs prescribe new A10Bs earlier than opinion-leading SPs due to higher 
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involvement in medical practice. Reflected in number of specialties earned and number of scientific 
publications, physicians’ scientific orientations do not increase the likelihoods of routine adoption. 
Furthermore, institutions with higher accreditation levels—such as clinics and university/teaching 
hospitals—do not play an opinion-leading role, new drugs diffusing equally fast to all institutions. 
Also, in synchronicity with Lin et al. (2011), physicians with more than one affiliation do not adopt 
new drugs earlier—theoretically, more affiliations allow for more interactions with colleagues, but 
the physicians sampled here were engaged in private solo practices, with no direct stimulus from 
colleagues. 
 
SPs’ age and gender played influential roles in the routine adoption of new drugs in approximately 
half of the earlier studies (Lublóy 2014). However, this article found no associations. Also, although 
almost all studies assessing the role of training location found it influential, this article found its 
impact marginal, which may be explained by the geographic proximity of training sites. 
 
This article surpasses previous studies in number and variety of variables—with so many different 
variables likely to influence new drug uptake, it is not surprising that the majority of variables have 
only a moderate impact. Another possible explanation for the insignificance of variables in this 
article compared to earlier studies may lie in investigating routine rather than first-time adoption of 
new drugs. 
 
5. Limitations 
 
This article has several possible limitations. First and foremost, prescription data is incomplete. 
SPs’ prescribing behaviors are monitored through the reported prescription data by GPs with whom 
SPs share patient care. All the sampled GPs included the name/identification number of the therapy-
initiating SPs, but only around one fifth of practicing GPs were sampled—SPs’ routine adoptions of 
new drugs may therefore occur earlier. However, the sampled GPs are geographically representative 
and the size of this bias is expected to be constant across SPs and not undermine the validity of the 
results. Second, the marketing efforts of pharmaceutical companies targeted at physicians are not 
accounted for. Detailing, sampling, advertisements in medical journals, and pharmaceutical 
meetings and events all aim to boost profits by providing knowledge, increasing product awareness, 
and directing further information acquisition. In the pharmaceutical marketing literature, the size 
and efficiency of marketing efforts targeted at physicians are very powerful predictors of new drug 
uptake (Kremer et al. 2008; Manchanda et al. 2008; Iyengar et al. 2011; Liu & Gupta 2012). Studies 
almost unambiguously reported that pharmaceutical marketing—particularly, detailing—has a 
significant positive influence on prescribing (for example, Kremer et al. 2008). Third, the contagion 
measure based on geographic proximity captures interpersonal effects indirectly—one cannot 
validate whether geographically close physicians exchange ideas regularly, if at all (for a detailed 
discussion of the benefits and costs of using geographic proximity, see Conley & Udry 2005). 
Fourth, conclusions based on only one therapeutic class cannot be generalized. By incorporating 
multiple therapeutic classes, future research may examine the determinants of new drug diffusion 
identified here for consistency and moderation by therapeutic class characteristics. 
 
6. Conclusions 
 
This article has explored the determinants that affect SPs’ routine prescribing of new A10Bs by 
focusing on the effects of six categories of factors—SPs’ social embeddedness, socio-demography, 
scientific orientation, and prescribing pattern, as well as practice and patient characteristics. A 
large-scale archival dataset of SPs’ actual prescribing behaviors has avoided several statistical 
biases usually related to retrospective surveys—for example, confounding bias, sample selection 
bias, and recall bias. This article has suggested practical ways in which pharmaceutical companies 
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and healthcare policy strategists may enhance new drug diffusion. Most importantly, echoing prior 
research, this article has found that knowledge regarding a new drug is—at least partly—socially 
constructed, and that previous prescribing patterns are decisive in new drug uptake. The former 
suggests that vicarious learning is as important as experimental learning, whereas the latter 
emphasizes the significance of SPs’ therapeutic convictions and clinical experiences. 
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